Takeda Pharmaceutical Company Ltd

Psoriasis, affecting 125M globally, is an immune-mediated disease with systemic implications. Takeda's TAK-279, a TYK2 inhibitor, showed promising Phase 2b results for psoriasis, moving to Phase 3. The psoriasis treatment landscape is evolving towards oral therapies, emphasizing convenience and targeted efficacy. Takeda focuses on diverse clinical trials and patient feedback, aiming for treatments that address broader immune-mediated conditions.

Vietnam's pharmaceutical industry faces challenges in high-tech drug production and technology transfer, aiming to become a regional hub. Despite progress, it meets only 70% of domestic drug demand. Legal reforms and investment incentives are crucial for growth and competitiveness.

The Colorectal Cancer market is projected to grow significantly by 2034, driven by increasing prevalence and advancements in treatment. Key companies include Mirati Therapeutics, AstraZeneca, and Takeda, with therapies like FRUZAQLA and ENHERTU gaining FDA approval. The US leads in cases, with a focus on metastatic and MSS mutation types. Regular screenings and research are crucial for managing this major public health challenge.

The cytomegalovirus (CMV) infections market is projected to grow at a CAGR of 4.32% from 2024 to 2034, driven by increased exposure to infected fluids, weakened immune systems, and the adoption of antiviral drugs and therapies. CMV, a herpesvirus, spreads through bodily fluids and can cause severe symptoms. The U.S. leads in patient pool and market size. Recent developments include new treatments and vaccines, highlighting the market's dynamic nature and potential for growth.

Opdivo Qvantig, the first subcutaneously administered PD-1 inhibitor, received FDA approval for treating adult solid tumors. Co-formulated with Halozyme's ENHANZE technology, it offers faster administration and comparable efficacy and safety to IV Opdivo, as shown in the Phase 3 CheckMate-67T trial.

Arrowhead Pharmaceuticals Inc. is developing Plozasiran, an RNAi therapeutic for Familial chylomicronemia syndrome (FCS), showing significant triglyceride reduction. Submitted NDA on Nov.18, 2024, with FDA review decision by Jan.18, 2025. Also exploring treatments for Severe Hypertriglyceridemia and Dyslipidemia.

Halozyme Therapeutics announced Takeda's HYQVIA® received Japanese regulatory approval for treating agammaglobulinemia or hypogammaglobulinemia, offering reduced dosing frequency with Halozyme's ENHANZE® technology.

Halozyme Therapeutics announced Japan's MHLW approved argenx's VYVDURA, co-formulated with Halozyme's ENHANZE® technology, for CIDP treatment. VYVDURA, a once-weekly subcutaneous injection, is the first FcRn blocker for CIDP, following its approval for gMG in Japan. The approval is based on the ADHERE Study, showing significant clinical improvement in patients.

Halozyme announced argenx's VYVDURA, co-formulated with ENHANZE®, received Japan's MHLW approval for CIDP treatment, marking the first FcRn blocker for CIDP. Approved for weekly self-administered subcutaneous injection, it follows ADHERE Study's positive outcomes, offering a new treatment option in Japan.

The Myasthenia Gravis Treatment Market is set to grow significantly by 2034, driven by improved diagnostics, emerging therapies, and increased awareness. Key companies like Horizon Therapeutics and Amgen are developing novel treatments. The market size reached USD 4,950 million in 2023, with the U.S. seeing 129 thousand cases.